【博腾股份:2024年基因细胞治疗CDMO业务新签订单1.75亿元,同比增长30%】金融界4月16日消息,博腾股份披露投资者关系活动记录表显示,2024年,公司在基因细胞治疗和小分子制剂等新业务领域持续取得进展,基因细胞治疗CDMO业务新签订单1.75亿元,同比增长30%;小分子制剂新签订单2.68亿元,同比增长19%。此外,公司的小分子原料药板块API产品收入为5.12亿元,增速为7%。

金融界
16 Apr
金融界4月16日消息,博腾股份披露投资者关系活动记录表显示,2024年,公司在基因细胞治疗和小分子制剂等新业务领域持续取得进展,基因细胞治疗CDMO业务新签订单1.75亿元,同比增长30%;小分子制剂新签订单2.68亿元,同比增长19%。此外,公司的小分子原料药板块API产品收入为5.12亿元,增速为7%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10